AR064225A1 - Derivados de 5- alquiloxi -indolin -2-ona- su preparacion y sus aplicaciones en terapeutica - Google Patents

Derivados de 5- alquiloxi -indolin -2-ona- su preparacion y sus aplicaciones en terapeutica

Info

Publication number
AR064225A1
AR064225A1 ARP070105529A ARP070105529A AR064225A1 AR 064225 A1 AR064225 A1 AR 064225A1 AR P070105529 A ARP070105529 A AR P070105529A AR P070105529 A ARP070105529 A AR P070105529A AR 064225 A1 AR064225 A1 AR 064225A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
mono
polyfluoro
substituted
Prior art date
Application number
ARP070105529A
Other languages
English (en)
Inventor
Gerard Valette
Lodc Foulon
Pierrick Rochard
Claudine Serradeil-Legal
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR064225A1 publication Critical patent/AR064225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)

Abstract

Se refiere asimismo al procedimiento de preparacion así como a las utilizaciones en terapéutica de los compuestos de formula (1). Reivindicacion 1: Compuesto que responde a la formula general (1): en la que R0 representa alquilo C1-4, mono o polifluoro-alquilo C1-4, -(CH2)n-ciclopropilo, o bien R0 representa alquenilo C2-4 o alquinilo C2-4; R1 representa un átomo de hidrogeno, alquilo C1-5, mono o polifluoro-alquilo C1-5, hidroxi-alquilo C1-5, -(CH2)m-cicIoalquilo C3-5; Z1 representa un átomo de hidrogeno o de halogeno, alquilo C1-4, mono o polifluoro-alquilo C1-4, alcoxi C1-4, mono o polifluoro-alcoxi C1-4, -(CH2)-ciclopropiIo, estando dicho grupo ciclopropilo no sustituido o sustituido con uno o varios átomos de fluor; Z2 representa un átomo de halogeno o un grupo T1W, en el que T1 representa un grupo -(CH2)n y W representa un átomo de hidrogeno, alquilo C1-4, mono o polifluoro-alquilo C1-4 o ciclopropilo no sustituido o sustituido con uno o varios átomos de fluor, o bien W representa un grupo -C(O)NR6R7 en el que R6 y R7 representan independientemente uno del otro un átomo de hidrogeno, alquilo C1-6, mono o polifluoro-alquilo C1-6 o -(CH2)-cicloalquilo C3-6, estando dicho grupo cicloalquilo no sustituido o sustituido con uno o varios átomos de fluor, un hidroxi, un grupo NRR', o bien R6, R7 representan independientemente uno del otro un grupo -(CH2)p- pirrolidinilo, -(CH2)p-piperidilo, -(CH2)p-piridilo, estando dichos grupos pirrolidinilo, piperidilo y piridilo no sustituidos o sustituidos con uno o más átomos de halogeno, alquilo C1-4, mono o polifluoro-alquilo C1-4, un bencilo o con un grupo -OR, o bien R6 y R7 representan independientemente uno del otro un grupo -(CH2)q-NRaRb, o bien R6 y R7 representan independientemente uno del otro un grupo -(CH2)s-C(O)NRaRb, o bien R6 y R7 representan independientemente uno del otro un grupo -(CH2)q-OR, o bien R6 y R7 forman junto con el átomo de nitrogeno al que están unidos un heterociclo monocíclico no sustituido o sustituido con uno o varios átomos de fluor, uno o varios grupos alquilo C1-4, mono o polifluoro-alquilo C1-4, -NR'R, u -OR; o bien R6 y R7 forman junto con el átomo de nitrogeno al que están unidos un heterociclo bicíclico no sustituido o sustituido con uno o varios átomos de fluor, alquilo C1-4, mono o polifluoro-alquilo C1-4, -OR o -NR'R; o bien W representa un grupo -NR8C(O)R9 en el que R8 representa un átomo de hidrogeno, alquilo C1-4, mono o polifluoro- alquilo C1-4, R9 representa un átomo de hidrogeno, alquilo C1-4, mono o polifluoro-alquilo C1-4, -(CH2)r-NRdRe, -(CH2)m-pirrolidinilo, -(CH2)m-piperidilo, -(CH2)m-piridilo, estando dichos grupos pirrolidinilo, piperidilo o piridilo no sustituidos o sustituidos con uno o varios grupos alquilo C1-4, halogeno, mono o polifluoro-alquilo C1-4, bencilo, o bien W representa un grupo -NR10R11 en el que R10 y R11 representan independientemente uno del otro un átomo de hidrogeno, un grupo hidroxi, alquilo C1-6 o un grupo mono o polifluoro-alquilo C1-6, o bien R10 y R11 forman junto con el átomo de nitrogeno al que están unidos un heterociclo monociclico no sustituido o sustituido con uno o varios grupos alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4 u oxo; o bien W representa un grupo -OR12 en el que R12 representa un átomo de hidrogeno, alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, un bencilo o un grupo -(CH2)q-NR'R; o bien W representa un grupo -C(O)OR19; R4 representa alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, un grupo -OR, alquenilo C2-4, nitro, COORc, un benciloxi, o bien R4 representa un grupo -C(O)NR13R14 en el que R13 y R14 representan independientemente uno del otro un átomo de hidrogeno, alquilo C1-6, estando dicho grupo alquilo no sustituido o sustituido con uno o varios átomos de fluor, un hidroxi, NRR', alcoxi C1-6-carbonilamino, alquiloxi C1-6-carbonilo, o en el que R13 y R14 representan independientemente uno del otro un grupo -(CH2)n-cicloalquilo C3-6, estando dicho grupo cicloalquilo no sustituido o sustituido con uno o varios átomos de fluor, o bien R4 representa un grupo -NR15R16 en el que R15 y R16 representan independientemente uno del otro un átomo de hidrogeno, un hidroxi, alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, -(CH2)-cicloalquilo C3-5, no sustituido o sustituido con uno o varios átomos de fluor, o bien R15 y R16 forman junto con el átomo de nitrogeno al que están unidos un heterociclo monociclico, o bien R4 representa un grupo -NR17C(O)R18 en el que R17 representa un átomo de hidrogeno, alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, R18 representa alquilo C1-6, un grupo mono o polifluoro-alquilo C1-6, -(CH2)n- cicloaIquilo C3-6, -NRdRe, fenilo, estando dicho fenilo él mismo no sustituido o sustituido con uno o varios grupos alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, R19 representa un átomo de hidrogeno, alquilo C1-6, un grupo mono o polifluoro- alquilo C1-6, -(CH2)q-NRaRb, -(CH2)q-OR, -(CH2)p-pirrolidinilo o -(CH2)-piperidilo, estando dichos grupos pirrolidinilo y piperidilo no sustituidos o sustituidos con uno o varios átomos de fluor, alquilo C1-4, un grupo mono o polifluoro-alquilo C1- 4, R3 y R5 representan independientemente uno del otro un átomo de hidrogeno, de halogeno, alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, alcoxi C1-4 o mono o polifluoro-alcoxi C1-4; Ra y Rb representan independientemente uno del otro: un átomo de hidrogeno, alquilo C1-4, un grupo mono o polifluoro-alquilo C1-4, -(CH2)n-ciclopropilo, estando dicho ciclopropilo no sustituido o sustituido con uno o varios átomos de fluor, o bien Ra y Rb forman junto con el átomo de nitrogeno al que están unidos un grupo heterociclo monociclo, estando dicho grupo heterociclo monociclo no sustituido o sustituido con uno o varios grupos hidroxilo, alquilo C1-4, mono o polifluoro-alquilo C1-4, alcoxi C1-4, mono o polifluoro-alcoxi C1-4, o con un grupo -NRR', R' y R representan independientemente uno del otro un átomo de hidrogeno, alquilo C1-4 o mono o polifluoro-alquilo C1-4, Rc representa un átomo de hidrogeno, alquilo C1-4, mono o polifluoro-alquilo C1-4 o un bencilo; Rd y Re representan independientemente uno del otro un átomo de hidrogeno, de halogeno, alquilo C1-6 o mono o polihalogeno-alquilo C1-6, o bien Rd y Re forman junto con el átomo de nitrogeno al que están unidos un grupo heterociclo monociclo, no sustituido o sustituido con uno o varios átomos de fluor, uno o varios grupos alquilo C1-4) o mono o polifluoro-alquiIo C1-4) o un grupo -OR; m puede representar el valor 0, 1 o 2, n puede representar el valor 0 o 1; p puede representar el valor 0, 1, 2 o 3; q puede representar el valor 2, 3, 4 o 5; r puede representar el valor 0, 1, 2, 3 o 4, s puede representar el valor 1, 2 o 3; en estado de base, de hidrato o de solvato, en forma de isomeros cis/trans o de sus mezclas.
ARP070105529A 2006-12-12 2007-12-11 Derivados de 5- alquiloxi -indolin -2-ona- su preparacion y sus aplicaciones en terapeutica AR064225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610803A FR2909668B1 (fr) 2006-12-12 2006-12-12 Derives de 5-alkyloxy-indolin-2-one,leur preparation et leurs applications en therapeutique

Publications (1)

Publication Number Publication Date
AR064225A1 true AR064225A1 (es) 2009-03-18

Family

ID=38261641

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105529A AR064225A1 (es) 2006-12-12 2007-12-11 Derivados de 5- alquiloxi -indolin -2-ona- su preparacion y sus aplicaciones en terapeutica

Country Status (12)

Country Link
US (1) US20100069384A1 (es)
EP (1) EP2097374B1 (es)
JP (1) JP5297386B2 (es)
AR (1) AR064225A1 (es)
AT (1) ATE470659T1 (es)
CL (1) CL2007003579A1 (es)
DE (1) DE602007007120D1 (es)
FR (1) FR2909668B1 (es)
PE (1) PE20081254A1 (es)
TW (1) TW200831481A (es)
UY (1) UY30782A1 (es)
WO (1) WO2008087278A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103380127B (zh) 2010-12-21 2016-08-10 拜耳知识产权有限责任公司 制备n-磺酰基取代的羟吲哚的方法
MX2013006694A (es) 2010-12-21 2013-07-29 Bayer Ip Gmbh Procedimiento para producir oxindoles sustituidos con triazinilo.
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
US20170204087A1 (en) * 2016-01-20 2017-07-20 Chemocentryx, Inc. 2-oxindole compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) * 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5726233A (en) * 1995-08-31 1998-03-10 Caterpillar Inc. Method for manufacturing a coating additive, an additive, and a paint formulation
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
FR2874920B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one comme ligand des recepteurs de la vasopressine
FR2874921B1 (fr) * 2004-09-09 2006-10-20 Sanofi Aventis Sa Derives de 3-spiro-indolin-2-one, leur preparation et leur application en therapeutique
FR2875499B1 (fr) * 2004-09-20 2006-10-27 Sanofi Aventis Sa Nouveaux derives pyridiniques d'indolin-2-one, leur preparation et leur application en therapeutique
US8030499B2 (en) * 2005-01-28 2011-10-04 Taisho Pharmaceutical Co., Ltd. 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle
WO2006100082A2 (de) * 2005-03-24 2006-09-28 Abbott Gmbh & Co. Kg Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung

Also Published As

Publication number Publication date
ATE470659T1 (de) 2010-06-15
FR2909668B1 (fr) 2009-01-23
PE20081254A1 (es) 2008-10-15
WO2008087278A3 (fr) 2008-09-18
EP2097374A2 (fr) 2009-09-09
WO2008087278A2 (fr) 2008-07-24
DE602007007120D1 (de) 2010-07-22
CL2007003579A1 (es) 2008-04-11
JP2010512374A (ja) 2010-04-22
JP5297386B2 (ja) 2013-09-25
US20100069384A1 (en) 2010-03-18
FR2909668A1 (fr) 2008-06-13
UY30782A1 (es) 2008-07-31
EP2097374B1 (fr) 2010-06-09
TW200831481A (en) 2008-08-01

Similar Documents

Publication Publication Date Title
BRPI0612888B8 (pt) anilino-piridinotriazinas cíclicas como inibidoras de gsk-3, seus usos e composição farmacêutica, intermediário, seu uso e composição farmacêutica
PE20151787A1 (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
PE20200700A1 (es) Compuestos macrociclicos y usos de los mismos
AR066669A1 (es) Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas.
AR086546A1 (es) Derivados de 7h-purin-8(9h)-ona como inhibidores de jak
AR046771A1 (es) Derivados piperidina-amino-bencimidazol como inhibidores de la replicacion del virus sincitial respiratorio
AR059571A1 (es) Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
AR057455A1 (es) Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AR071617A1 (es) Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos.
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
AR074336A1 (es) Compuestos de arilo con sustituyentes heterociclicos y su uso
ECSP11010901A (es) Compuestos de amida útiles en terapia
AR045687A1 (es) Macrociclos derivados de la quinazolina, procesos de preparacion y composiciones farmaceuticas que los contienen
AR069765A1 (es) 4-(4-ciano) 2- tioaril) dihidropirimidonas y su uso
UY31730A (es) Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridinas, su preparación y su aplicación en terapéutica.
AR076859A1 (es) Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos.
PH12016500234A1 (en) Tricyclic benzoxaborole compounds and uses thereof
AR068734A1 (es) Esteroides con actividad agonista del receptor de glucocorticoides
AR047466A1 (es) Compuestos derivados de 3h - imidazo[4,5 - b]piridina con actividad inhibidora de quinasa, composiciones farmacéuticas que los contienen como principio activo y su uso en la fabricacion de un medicamento para el tratatmiento de neoplasmas susceptibles.
AR064225A1 (es) Derivados de 5- alquiloxi -indolin -2-ona- su preparacion y sus aplicaciones en terapeutica
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
MY194004A (en) 4 -substituted benzoxaborole compounds and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure